Skip to Content

Humalog Side Effects

Generic Name: insulin lispro

Note: This page contains information about the side effects of insulin lispro. Some of the dosage forms included on this document may not apply to the brand name Humalog.

Not all side effects for Humalog may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to insulin lispro: suspension

In addition to its needed effects, some unwanted effects may be caused by insulin lispro (the active ingredient contained in Humalog). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking insulin lispro:

More common
  • Anxious or nervous feeling
  • behavior change similar to being drunk
  • blurred vision
  • cold sweats
  • confusion or difficulty thinking
  • convulsions (seizures)
  • depression
  • dizziness or lightheadedness
  • drowsiness
  • excessive hunger
  • fast heartbeat
  • fever or chills
  • headache
  • irritability or abnormal behavior
  • lower back or side pain
  • nightmares
  • painful or difficult urination
  • restless sleep
  • shakiness
  • slurred speech
  • tingling in the hands, feet, lips, or tongue
  • unconsciousness
Less common
  • Dry, red, hot, or irritated skin
Less common or rare
  • Depression of the skin at the injection site
  • dryness of the mouth
  • fast or weak pulse
  • itching, redness, or swelling at the injection site
  • muscle cramps or pain
  • nausea or vomiting
  • shortness of breath
  • skin rash or itching over the whole body
  • sweating
  • thickening of the skin at the injection site
  • unusual tiredness or weakness
  • wheezing
Incidence not known
  • Bloating or swelling of the face, arms, hands, lower legs, or feet
  • decreased urine
  • difficult or labored breathing
  • difficulty with swallowing
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fast, pounding, or irregular heartbeat or pulse
  • hives or itching skin
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • redistribution or accumulation of body fat
  • tightness in the chest
  • unusual weight gain or loss

Some of the side effects that can occur with insulin lispro may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Body aches or pain
  • congestion
  • runny nose
  • sneezing
  • stuffy nose
  • tender, swollen glands in the neck
  • voice changes
Incidence not known
  • Redness, swelling, or itching at the injection site

For Healthcare Professionals

Applies to insulin lispro: subcutaneous solution

General

Adverse reactions observed have included hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.[Ref]

Metabolic

Weight gain has been reported with insulin therapy and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.[Ref]

Very common (10% or more): Hypoglycemia
Frequency not reported: Weight gain[Ref]

Hypersensitivity

Frequency not reported: Allergic reactions including anaphylaxis[Ref]

Hypersensitivity side effects have included both local and systemic reactions. Anaphylaxis has been reported. Local reactions have presented as erythema, local edema, and pruritus at the injection site. Most minor reactions to insulin at the injection site resolve in a few days to a few weeks.

Generalized allergy to insulin may present as a whole body rash, dyspnea, wheezing, hypotension, tachycardia, or diaphoresis. In clinical trials, pruritus (with or without rash) was seen in 17 patients receiving human insulin (n=2969) and 30 patients receiving insulin lispro (n=2944).[Ref]

Local

Common (1% to 10%): Infusion site reactions
Rare (less than 0.1%): Catheter occlusions/month[Ref]

Ocular

Rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder and worsening of diabetic retinopathy. However, long-term glycemic control decreases the risk of diabetic retinopathy.[Ref]

Uncommon (0.1% to 1%): Refraction disorder, worsening of diabetic retinopathy[Ref]

Nervous system

Very common (10% or more): Headache (up to 29.6%)
Rare (less than 0.1%): Painful peripheral neuropathy[Ref]

Rapid improvement in glucose control has been associated with a transitory, reversible acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk.[Ref]

Immunologic

The clinical significance of the development of these antibody titers is unknown.[Ref]

Very common (10% or more): Flu syndrome (up to 34.6%), infection (up to 13.6%)
Frequency not reported: Anti-insulin antibody titers[Ref]

Cardiovascular

Frequency not reported: Peripheral edema[Ref]

Insulin may cause sodium retention and edema, especially as metabolic control is improving.[Ref]

Dermatologic

Long-term use of insulin may cause lipodystrophy at the site of repeated injection. Lipodystrophy includes lipohypertrophy, a thickening of adipose tissue, and lipoatrophy, thinning of adipose tissue.[Ref]

Uncommon (0.1% to 1%): Urticaria, rash
Frequency not reported: Lipodystrophy including lipohypertrophy and lipoatrophy[Ref]

Gastrointestinal

Common (1% to 10%): Nausea, diarrhea, abdominal pain[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection, dysmenorrhea[Ref]

Musculoskeletal

Common (1% to 10%): Myalgia[Ref]

Other

Very common (10% or more): Pain (up to 19.8%)
Common (1% to 10%): Fever[Ref]

Respiratory

Very common (10% or more): Pharyngitis (up to 33.3%), rhinitis (up to 24.7%), increased cough (up to 17.3%)
Common (1% to 10%): Sinusitis, bronchitis[Ref]

References

1. "Product Information. Humalog (insulin lispro)." Lilly, Eli and Company, Indianapolis, IN.

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web3)